Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-Guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
NCT03791905Phase 2Unknown
- Sponsor
- Mianxi Biopharma
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, cisplatin, oxaliplatin, fluorouracil and folinic acid in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Mianxi Biopharma. Primary endpoint: Clinical Complete Response at 3 months. Status: unknown.
02
Drugs
paclitaxelcisplatinoxaliplatinfluorouracilfolinic acid
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03791905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791905.